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Abstract
Background: Acute interstitial nephritis (AIN) is an important cause of reversible acute kidney injury. At least 70%
of AIN is caused by various drugs, mainly penicillines and non-steroidal anti-inflammatory drugs. Quinolones are
only rarely known to cause AIN and so far cases have been mainly described with older fluoroquinolones.
Case Presentation: Here we describe a case of biopsy proven interstitial nephritis after moxifloxacin treatment.
The patient presented with fever, rigors and dialysis dependent acute kidney injury, just a few days after treatment
of a respiratory tract infection with moxifloxacin. The renal biopsy revealed dense infiltrates mainly composed of
eosinophils and severe interstitial edema. A course of oral prednisolone (1 mg/kg/day) was commenced and
rapidly tapered to zero within three weeks. The renal function improved, and the patient was discharged with a
creatinine of 107 μmol/l.
Conclusion: This case illustrates that pharmacovigilance is important to early detect rare side effects, such as AIN,
even in drugs with a favourable risk/benefit ratio such as moxifloxacin.
Background
Acute interstitial nephritis (AIN) is an important cause
of reversible acute kidney injury [1]. It is demonstrated
in 2-3% of all native renal biopsies, increasing to 10-15%
in the setting of acute kidney injury [2]. The etiology of
at least two thirds of all cases is thought to be drug-
induced [3]. Although methicillin and other b-lactam
antibiotics are the prototype offending agents for many
years and are causative in about a third of all drug
induced AIN, numerous other medications have been
incriminated. Despite the enormous clinical and market-
ing success fluoroquinolones have enjoyed over the past
20 years, this group has only rarely been linked to AIN.
There are about 30 case reports that the most widely
used group II fluoroquinolones (ciprofloxacin and oflox-
acin) which exhibit mainly activity against Gram-nega-
tive bacteria can cause AIN [4]. Recently group III
(levofloxacin) and group IV fluoroquinolones (moxiflox-
acin), which show an improved activity against Gram-
positive pathogens while maintaining similar activity
against many Gram-negative bacteria, have been increas-
i n g l yu s e d[ 5 ] .A l t h o u g ht h e r ea r es o m er e p o r t st h a t
levofloxacin can induce AIN [6] there has been only a
report linking moxifloxacin to biopsy proven AIN [7].
We report here another interesting case of a biopsy
proven AIN caused by a novel quinolone antibiotic, i.e.,
moxifloxacin.
Case presentation
A 65 year old man was admitted with fever, rigors and
oliguric acute kidney injury. One month earlier the
patient had undergone unilateral (right) pneumectomy
due to a newly diagnosed non-small cell lung cancer
(pT3N0M0). Twenty days after the operation the patient
was discharged from the hospital with instructions to
complete a two week treatment course with moxifloxa-
cin (400 mg/d) due to a suspected pneumonia facilitated
by pleural effusion. He did not receive any other drugs
during this hospital stay. Four days after having stopped
taking moxifloxacin and nearly one week before the cur-
rent admission fever (40°C), a sensation of chilliness,
watery diarrhoea and worsening oliguria occurred. His
symptoms did not improve and he finally presented in
the emergency department of our hospital. On admis-
sion his temperature was 38°C. The blood pressure was
120/60 mmHg, the pulse 80 per minute, the respiratory
rate 25 breaths per minute and the oxygen saturation
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On physical examination, there was no rash or lympha-
denopathy and no petechiae were found. The jugular
veins were not distended, the left lung was clear and the
heart sounds were normal. His abdomen was soft, with
normal bowel sounds and no tenderness or hepatosple-
nomegaly. There was no peripheral edema and the
pulses at the hands and feet were palpable. Neurologic
examination was unremarkable. The laboratory studies
were notable for leukocytosis with no leftward shift and
eosinophilia, mild anaemia and normal platelet count
(WBC = 14000 μl, with 51% eosoinophils, hematocrit
32.6%, hemoglobin11.8 g/dl, PLT = 304.000/μl). His
serum creatinine level had increased from 95 μmol/l at
discharge one month earlier to 1204 μmol/l. The urine
dipstick was ++ for protein, ++ for hemoglobin. The
sediment contained 1-4 red cells, 5-10 white cells, and
no casts or crystals. Eosinophiluria was not present in
the phase contrast microscopy, though specific stains
(such as Hansel’s stain) were not performed.
Due to acute kidney injury dialysis therapy was
initiated. A renal biopsy was also performed. The speci-
men contained 6 glomeruli none of which was sclerotic.
The glomeruli appeared unremarkable but a severe
interstitial inflammation with edema was observed. The
infiltrates were composed nearly totally of eosinophils;
Eosinophils were also seen invading the tubules beneath
the tubular basement membrane as well as within the
tubular lumen. Minimal interstitial fibrosis was accom-
panied by minimal tubular atrophy. Small arteries pre-
sent in the biopsy specimen showed mild hyalinosis
(Figure 1). Immunohistochemistry for IgA, IgM IgG, C3,
C4, kappa and lambda chains was completely negative.
Electron microscopy was not performed, due to the
unambiguous diagnosis and the good clinical response.
A course of oral prednisolone (1 mg/kg/day) was com-
menced and rapidly tapered to zero within three weeks.
The renal function improved, and the patient was dis-
charged with a creatinine of 107 μmol/l (Figure 2).
Discussion and Conclusions
Drug-induced acute interstitial nephritis (DI-AIN) repre-
sents a significant cause of acute kidney injury. It is
characterized by inflammation and scarring that is con-
fined largely to the tubular and interstitial compart-
ments with sparing of the glomeruli and the vasculature.
The infiltrates are largely composed of T cells, together
with some macrophages, plasma cells and eosinophils
[8]. Antibiotics and non-steroidal anti-inflammatory
drugs (NSAIDs) are the most frequently implicated
agents, but the list of drugs that can induce a DI-AIN is
continuously increasing. The mechanism of injury is
postulated to involve cell mediated immunity [9,10] and
the syndrome is often associated with extrarenal mani-
festations of hypersensitivity, such as rash, fever and
eosinophilia. But recent studies document that the full
hypersensitivity triad is not often present and suspicion
of AIN should still arise if any of these features is pre-
sent in patients with renal failure on suspect medica-
tions [10,11]. Renal manifestations develop within three
weeks after starting the inciting drug in about 80% of
patients, with an average delay of about ten days. The
clinical presentation most suggestive of the diagnosis is
that of a sudden impairment of renal function associated
Figure 1 Light microscopy of the kidney biopsy specimen
shows interstitial edema with eosinophilic infiltrates.
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patient with flank pain, normal blood pressure and no
edema. Nevertheless, such a clinical picture is observed
in less than one -fourth of cases [8].
Analysis of published cases of AIN induced by drugs
other than methicillin show that nowadays the course of
AIN is far from always being benign, and that serum
creatinine level remains elevated in about 40% of
patients. Bad prognostic indicators are the duration of
renal failure (> 3 weeks), age and the degree of intersti-
tial fibrosis [12,13]. According to some reports intersti-
tial fibrosis can begin occurring in AIN as soon as 10 to
14 days after disease induction.
Despite the above data, the optimal therapy of AIN
remains to be defined. A general agreement exists about
the discontinuation of the offending drug as the first
therapeutic step in patients with DI-AIN, but contro-
versy persists about the role of steroids in the treatment
of DI-AIN. Whereas some studies have reported a more
rapid and complete recovery of baseline renal function
in those patients treated with steroids, others have failed
to confirm these results. A recently published multicen-
ter retrospective study involving 61 patients, suggested a
beneficial influence of corticosteroids on the outcome of
drug-induced AIN. An earlier onset of use (13 versus 34
days) was associated with a better recovery of renal
function [14].
Both cases illustrate that moxifloxacin induced AIN
represents a reversible cause of acute kidney injury. Of
note, the classical clinical features were absent in our
patient and his renal function recovered fully despite
dialysis dependency at presentation. Notably, in the
other reported case, where diagnosis was made 10 days
and treatment with corticosteroids was initiated only
two weeks after the onset of symptoms, the restoration
of renal function was delayed and residual proteinuria
persisted. Therefore increased vigilance is required to
identify the emergence of new toxic compounds and
early renal biopsy is recommended in cases of acute kid-
ney injury in patients taking moxifloxacin. The early use
of corticosteroids should be considered in patients with
moxifloxacin induced AIN.
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